CN107428817B - 纯化白蛋白融合蛋白的方法 - Google Patents

纯化白蛋白融合蛋白的方法 Download PDF

Info

Publication number
CN107428817B
CN107428817B CN201680014597.2A CN201680014597A CN107428817B CN 107428817 B CN107428817 B CN 107428817B CN 201680014597 A CN201680014597 A CN 201680014597A CN 107428817 B CN107428817 B CN 107428817B
Authority
CN
China
Prior art keywords
sequence
comprises seq
loop comprises
seq
loop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680014597.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107428817A (zh
Inventor
T.帕布斯特
M.丰塞卡
C.汤普森
A.亨特
王向阳
铁柳
Y.李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CN107428817A publication Critical patent/CN107428817A/zh
Application granted granted Critical
Publication of CN107428817B publication Critical patent/CN107428817B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680014597.2A 2015-03-12 2016-03-11 纯化白蛋白融合蛋白的方法 Active CN107428817B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562132198P 2015-03-12 2015-03-12
US62/132198 2015-03-12
PCT/US2016/022003 WO2016145307A1 (en) 2015-03-12 2016-03-11 Method of purifying albumin-fusion proteins

Publications (2)

Publication Number Publication Date
CN107428817A CN107428817A (zh) 2017-12-01
CN107428817B true CN107428817B (zh) 2022-07-12

Family

ID=56878920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680014597.2A Active CN107428817B (zh) 2015-03-12 2016-03-11 纯化白蛋白融合蛋白的方法

Country Status (10)

Country Link
US (3) US10683340B2 (enExample)
EP (2) EP3268389B1 (enExample)
JP (4) JP6862348B2 (enExample)
KR (2) KR20170124592A (enExample)
CN (1) CN107428817B (enExample)
AU (4) AU2016228806B2 (enExample)
CA (2) CA3260163A1 (enExample)
ES (1) ES2839211T3 (enExample)
IL (1) IL253971B (enExample)
WO (1) WO2016145307A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102434073B1 (ko) 2011-10-11 2022-08-18 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3793612A4 (en) 2018-05-16 2022-03-02 LIB Therapeutics, LLC COMPOSITIONS CONTAINING PCSK9 BINDING MOLECULES AND METHODS OF USE
BR112021008797A2 (pt) * 2018-11-09 2021-08-31 Neopep Pharma Gmbh & Co. Kg Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
EP3711772A1 (en) * 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN110295152A (zh) * 2019-07-29 2019-10-01 北京泓恩生物科技有限公司 一种重组产朊假丝酵母尿酸酶的纯化方法
IL309560B2 (en) * 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
EP4175969A4 (en) * 2020-07-01 2024-07-24 Medimmune, LLC DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPY AGENT
CN112062833A (zh) * 2020-10-09 2020-12-11 国药集团武汉血液制品有限公司 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法
CN115677848A (zh) * 2022-10-24 2023-02-03 通化安睿特生物制药股份有限公司 一种制备高纯度高稳定性蛋白质的方法
CN120712138A (zh) * 2022-10-25 2025-09-26 唐纳森公司 含有碳水化合物结合结构域的分子的分离介质和纯化方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570916A2 (en) * 1992-05-20 1993-11-24 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
CN1902224A (zh) * 2003-12-04 2007-01-24 Cj株式会社 纯化β－干扰素的方法
CN102549012A (zh) * 2009-05-07 2012-07-04 诺维信生物制药丹麦公司 纯化白蛋白的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
CA2079802C (en) 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
CA2350417C (en) 1998-12-02 2010-02-09 Bristol-Myers Squibb Company Dna-protein fusions and uses thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2377468C (en) 1999-07-27 2010-04-20 Phylos, Inc. Peptide acceptor ligation methods
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
WO2003000856A2 (en) 2001-06-21 2003-01-03 Phylos, Inc. In vitro protein interaction detection systems
ATE528396T1 (de) 2004-07-06 2011-10-15 Bioren Inc Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
AU2006329215A1 (en) 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
JP5518702B2 (ja) 2007-07-03 2014-06-11 ダヌタ・クルセフスカ α−ケトグルタレートの新規の医学的用途
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
EP2215246B1 (en) 2007-10-31 2015-01-07 MedImmune, LLC Protein scaffolds
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
WO2011103076A1 (en) 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
KR20130056870A (ko) 2010-04-13 2013-05-30 메디뮨 엘엘씨 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드
EP2675471A4 (en) 2011-02-15 2015-01-28 Medimmune Llc HSA-RELATED COMPOSITIONS AND USE PROCESSES
KR102434073B1 (ko) * 2011-10-11 2022-08-18 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
CA2890766A1 (en) * 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570916A2 (en) * 1992-05-20 1993-11-24 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
CN1902224A (zh) * 2003-12-04 2007-01-24 Cj株式会社 纯化β－干扰素的方法
CN102549012A (zh) * 2009-05-07 2012-07-04 诺维信生物制药丹麦公司 纯化白蛋白的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIC resolution of an IgG1 with an oxidized Trp in a complementarity determining region;DanielBoyd et al.;《Journal of Chromatography B》;20110310;第879卷(第13-14期);第955-960页 *

Also Published As

Publication number Publication date
US20200407423A1 (en) 2020-12-31
US11548933B2 (en) 2023-01-10
ES2839211T3 (es) 2021-07-05
AU2023204271B2 (en) 2026-04-02
AU2016228806B2 (en) 2020-10-22
CA2977675A1 (en) 2016-09-15
US20230340074A1 (en) 2023-10-26
KR20240093725A (ko) 2024-06-24
JP7826243B2 (ja) 2026-03-09
JP6862348B2 (ja) 2021-04-21
IL253971A0 (en) 2017-10-31
AU2016228806A1 (en) 2017-08-31
JP2023103368A (ja) 2023-07-26
KR20170124592A (ko) 2017-11-10
JP2018513124A (ja) 2018-05-24
IL253971B (en) 2021-10-31
AU2021200423A1 (en) 2021-02-25
AU2026201911A1 (en) 2026-04-02
CA3260163A1 (en) 2026-03-02
US20180105575A1 (en) 2018-04-19
EP3268389A1 (en) 2018-01-17
US10683340B2 (en) 2020-06-16
EP3268389B1 (en) 2020-09-30
AU2023204271A1 (en) 2023-07-27
JP2026094244A (ja) 2026-06-09
AU2021200423B2 (en) 2023-04-06
JP7320550B2 (ja) 2023-08-03
JP2021105025A (ja) 2021-07-26
EP3842451A1 (en) 2021-06-30
BR112017019401A2 (pt) 2018-05-02
WO2016145307A1 (en) 2016-09-15
CN107428817A (zh) 2017-12-01
EP3268389A4 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
JP7826243B2 (ja) アルブミン融合タンパク質を精製する方法
JP7744391B2 (ja) 抗ｖｅｇｆタンパク質組成物及びその製造方法
JP7583411B2 (ja) Ｆｃ領域改変抗体の精製方法
US20250215050A1 (en) Compositions and methods for purifying biological fluids
KR20250148832A (ko) 알부민 융합 단백질의 정제방법
HK1245286B (en) Method of purifying albumin-fusion proteins
BR112017019401B1 (pt) Método de purificação de proteínas de fusão de albumina
BR122024023456A2 (pt) COMPOSIÇÃO COMPREENDENDO SUPORTES Tn3
HK40061321A (en) Method for purifying fc region-modified antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant